specialty pharmaceutical company
Company profile
Ticker
EGRX
Exchange
Website
CEO
Scott Tarriff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EAGLE PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Eagle Biologics, Inc. • Eagle Research Lab Limited • Acacia Pharma Group plc • Acacia Pharma Limited • Acacia Pharma Inc ...
EGRX stock data
Latest filings (excl ownership)
8-K
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Forward-Looking Statements Disclaimer
12 Apr 24
NT 10-K
Notice of late annual filing
18 Mar 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Cost Associated with Exit or Disposal Activities
29 Feb 24
8-K
Other Events
13 Feb 24
8-K
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
18 Jan 24
8-K
Entry into a Material Definitive Agreement
16 Jan 24
8-K/A
Departure of Directors or Certain Officers
22 Dec 23
8-K
Results of Operations and Financial Condition
15 Dec 23
Transcripts
EGRX
Earnings call transcript
2023 Q1
9 May 23
EGRX
Earnings call transcript
2022 Q4
13 Mar 23
EGRX
Earnings call transcript
2022 Q3
7 Nov 22
EGRX
Earnings call transcript
2022 Q2
9 Aug 22
EGRX
Earnings call transcript
2022 Q1
9 May 22
EGRX
Earnings call transcript
2021 Q4
7 Mar 22
EGRX
Earnings call transcript
2021 Q3
9 Nov 21
EGRX
Earnings call transcript
2021 Q2
9 Aug 21
EGRX
Earnings call transcript
2021 Q1
10 May 21
EGRX
Earnings call transcript
2020 Q4
2 Mar 21
Latest ownership filings
SC 13G/A
Tarriff Scott
18 Mar 24
4
Scott Tarriff
1 Mar 24
4
Brian Joseph Cahill
29 Feb 24
4
Scott Tarriff
29 Feb 24
SC 13D
Graves Michael
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G
BRANDES INVESTMENT PARTNERS, LP
12 Feb 24
SC 13G
HIRSCHMAN ORIN
7 Feb 24
4
Brian Joseph Cahill
6 Feb 24
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.35 mm | 15.35 mm | 15.35 mm | 15.35 mm | 15.35 mm | 15.35 mm |
Cash burn (monthly) | 2.18 mm | 1.77 mm | (no burn) | (no burn) | 42.00 k | 776.50 k |
Cash used (since last report) | 21.64 mm | 17.54 mm | n/a | n/a | 416.74 k | 7.70 mm |
Cash remaining | -6.29 mm | -2.18 mm | n/a | n/a | 14.94 mm | 7.65 mm |
Runway (months of cash) | -2.9 | -1.2 | n/a | n/a | 355.6 | 9.9 |
Institutional ownership, Q3 2023
86.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 107 |
Opened positions | 12 |
Closed positions | 31 |
Increased positions | 31 |
Reduced positions | 48 |
13F shares | Current |
---|---|
Total value | 151.33 bn |
Total shares | 11.29 mm |
Total puts | 1.30 k |
Total calls | 1.40 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
JHG Janus Henderson | 1.14 mm | $18.00 bn |
Brandes Investment Partners | 1.13 mm | $17.89 bn |
Scott Tarriff | 992.62 k | $0.00 |
BLK Blackrock | 889.08 k | $14.02 bn |
Vanguard | 643.60 k | $10.15 bn |
Adage Capital Partners GP, L.L.C. | 500.00 k | $7.89 bn |
LSV Asset Management | 408.76 k | $6.45 mm |
Millennium Management | 347.53 k | $5.48 bn |
Citadel Advisors | 292.16 k | $4.61 bn |
Aqr Capital Management | 282.96 k | $4.46 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | Scott Tarriff | Common Stock | Payment of exercise | Dispose F | No | No | 6.27 | 2,119 | 13.29 k | 460,621 |
27 Feb 24 | Scott Tarriff | Common Stock | Payment of exercise | Dispose F | No | No | 6.44 | 3,154 | 20.31 k | 462,740 |
27 Feb 24 | Scott Tarriff | Common Stock | Grant | Acquire A | No | No | 0 | 12,950 | 0.00 | 465,894 |
27 Feb 24 | Brian Joseph Cahill | Common Stock | Payment of exercise | Dispose F | No | No | 6.44 | 1,589 | 10.23 k | 47,958 |
27 Feb 24 | Brian Joseph Cahill | Common Stock | Grant | Acquire A | No | No | 0 | 3,800 | 0.00 | 49,547 |
2 Feb 24 | Brian Joseph Cahill | Common Stock | Payment of exercise | Dispose F | No | No | 5.85 | 934 | 5.46 k | 45,747 |
5 Jan 24 | Brian Joseph Cahill | Common Stock | Payment of exercise | Dispose F | No | No | 5.13 | 735 | 3.77 k | 46,681 |
Press releases
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
12 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX
11 Feb 24
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
9 Feb 24
Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX
9 Feb 24
EGRX DEADLINE TOMORROW: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX
8 Feb 24